Effects of artemisinin on proliferation and apoptosis of human liver cancer HepG2 cells
A protocol of systematic review and meta-analysis

Jing Li, MM1, Zhi-ye Liu, MB2, Hai-bo Yu, MM3, Qing Xue, MB candidate4, Xiu-sheng Qu, MMb,∗

Abstract
Background: This study will examine the effects of artemisinin on proliferation and apoptosis of human liver cancer HepG2 cells (HLCHG-2C).

Methods: This study will systematically retrieve potential literatures in MEDLINE, Scopus, Web of Science, Cochrane Library, EMBASE, WANGFANG, and China National Knowledge Infrastructure from their initiation to the February 29, 2020. There are no limitations related to the language and publication time. All case-controlled studies (CCSs) or randomized controlled studies (RCSs) will be included in this study which investigated the effects of artemisinin on proliferation and apoptosis of HLCHG-2C. Two independent investigators will examine searched records, collect data from included studies, and will identify their methodological quality. Any divergences will be disentangled by discussion with another investigator. RevMan 5.3 software will be placed to pool the data and to carry out data analysis.

Results: This study will summarize all eligible studies to test the effects of artemisinin on proliferation and apoptosis of HLCHG-2C.

Conclusion: The results of this study will exert evidence to examine the effects of artemisinin on proliferation and apoptosis of HLCHG-2C, and it may benefit further research, patients, and healthcare providers.

Systematic review registration: INPLASY202040075.

Abbreviations: CCSs = case-controlled studies, CIs = confidence intervals, HCC = hepatocellular carcinoma, HLCHG-2C = human liver cancer HepG2 cells, LC = liver cancer, PRISRMA = Preferred Reporting Items for Systematic Reviews and Meta-Analysis, RCSs = randomized controlled studies.

Keywords: artemisinin, effect, human liver cancer HepG2 cells

1. Introduction
Primary liver cancer (LC) is one of the most common malignant tumors.1–4 Its incidence is about 1 million new cases each year globally.5,6 Of that, hepatocellular carcinoma (HCC) accounts for about 90% of all LC.7 Thus, it is very important to treat patients with HCC. A variety of treatments have reported to treat patients with HCC, their efficacy is still not limited8–14 Thus, it is very urgent to find more effective medications to treat such condition.

Previous study reported that cellular immunotherapy has been increasingly used for the treatment of HCC.15 Recent experimental studies have found that artemisinin can manage the proliferation and apoptosis of human liver cancer HepG2 cells (HLCHG-2C),16–23 which is a potential candidate for HCC therapy in the clinical practice. However, no systematic review is identified to appraise the effects of artemisinin on proliferation and apoptosis of HLCHG-2C.

2. Methods

2.1. Study registration
This study was registered and funded on INPLASY202040075, and it has been reported based on the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) Protocol statement.24,25

2.2. Eligibility criteria

2.2.1. Types of trials. All potential case-controlled studies (CCSs) or randomized controlled studies (RCSs) will be included, which explore the effects of artemisinin on proliferation and apoptosis of HLCHG-2C. We will not consider any other studies, such as review, comment, and uncontrolled studies.
2.2.2. Types of subjects. This study will include HLCHG-2C as its targeted subject.

2.2.3. Types of exposures/interventions. In the experimental group, all HLCHG-2C were managed using artemisinin. However, we will exclude studies that utilized combination of artemisinin with other treatments.

In the control group, all treatment options were available for HLCHG-2C. However, we will not consider studies employed any types of artemisinin as their control management.

2.2.4. Types of outcome measurements. Primary outcome is proliferation and apoptosis of HLCHG-2C. Its proliferation is examined by cell viability test, and its apoptosis is detected by flow cytometry.

Secondary outcomes include HLCHG-2C proliferation and apoptosis related-proteins and genes expression. The proteins (including β-catenin, PTEN, Akt, CyclinD1, P27, Bax, Bcl-2, Caspase-3, Caspase-9, Cytochrome-C, and PCNA) are measured by immunofluorescence or western blot test. The genes (including Mcl-1 and Caspase-3) are identified by Real-time polymerase chain reaction or relevant test.

2.3. Literature sources and search strategy

Electronic databases will be systematically searched potential studies in MEDLINE, Scopus, Web of Science, Cochrane Library, EMBASE, WANGFANG, and China National Knowledge Infrastructure from their initiation to the February 29, 2020, regardless language and publication time restrictions. We will include all potential CCSs or RCSs that identified the effects of artemisinin on proliferation and apoptosis of HLCHG-2C. A search strategy sample for MEDLINE is summarized (Table 1).

We will also provide similar search strategies for other electronic databases.

In addition, we will examine other sources to avoid missing more potential studies, such as Google Scholar, reports on related agencies, conference proceedings, and reference lists of relevant reviews.

2.4. Study selection

Two investigators will independently carry out primary article scanning according to the predefined eligibility criteria. First, titles/abstracts of sought literatures will be screened to eliminate unconnected studies and duplicates. Second, full papers of potential studies will be further examined in accordance with the full inclusion criteria. Any differences will be figured out by discussion with another investigator. The results of study selection will be shown in a PRISMA flow diagram with details.

2.5. Data collection and management

Before data collection, a standardized data extraction sheet will be developed to collect relate study data from all eligible studies. Two investigators will independently collect following data: publication information (along with author name and publication time), HLCHG-2C information, study setting and design, interventions and comparators (such as names and types of treatments, dosage, etc), outcomes, results, findings, and conflict of interest. Any disagreements will be worked out by consultation with another investigator. Any insufficient or missing information will be obtained from original authors by email or telephone.

2.6. Study quality assessment

The study quality will be independently appraised by 2 investigators using Newcastle-Ottawa Scale for CCSs and Cochrane risk of bias tool for RCSs. Any different opinions will be arbitrated with another investigator.

2.7. Statistical analysis

2.7.1. Data synthesis. This study will apply RevMan 5.3 software to synthesize and analyze extracted data. We will calculate treatment effects of pooled dichotomous data as risk ratio and 95% confidence intervals (CIs), and synthesized continuous data as weighted mean difference or standardized mean difference and 95% CIs. Heterogeneity across studies will be assessed using Higgins I² statistic. I² < 50% is considered as having minimal heterogeneity and data will be pooled using a fixed-effects model, while I² > 50% is regarded as suggesting substantial heterogeneity and data will be synthesized using a random-effects model. When there is minimal heterogeneity, we will arrange to conduct a meta-analysis if possible. Otherwise, when there is significant heterogeneity, we will carry out a subgroup analysis to investigate possible sources of substantial heterogeneity.

2.7.2. Subgroup analysis. If necessary, this study will carry out a subgroup analysis to test the sources of heterogeneity in accordance with the different types of studies, study quality, and intervention and controls.

2.7.3. Sensitivity analysis. Whenever possible, this study will conduct a sensitivity analysis to examine the robustness and stability of study findings by removing low quality studies.

2.7.4. Reporting bias. This study will plan to explore a funnel plot and Egger’s regression test to identify reporting bias if over 10 studies are included.
2.8. Dissemination and ethics

This study will not analyze individual patient data, thus, no ethical approval will be provided. It will be disseminated on a peer-reviewed journal or conference presentation.

3. Discussion

Although previous studies have reported the effects of artemisinin on proliferation and apoptosis of HLCHG-2C,[16–23] no study has accumulated sufficient evidence to draw definitive conclusions on this topic. Thus, this study will systematically and comprehensively assess the effects of artemisinin on proliferation and apoptosis of HLCHG-2C. The results of this study will provide helpful evidence to explore a potential candidate for HCC therapy in the clinical practice.

Author contributions

Conceptualization: Jing Li, Zhi-ye Liu, Qing Xue.
Data curation: Hai-bo Yu, Xiusheng Qu.
Formal analysis: Jing Li, Zhi-ye Liu, Qing Xue.
Investigation: Xiusheng Qu.
Methodology: Hai-bo Yu, Qing Xue.
Project administration: Xiusheng Qu.
Resources: Jing Li, Zhi-ye Liu, Hai-bo Yu, Qing Xue.
Software: Jing Li, Zhi-ye Liu, Hai-bo Yu, Qing Xue.
Supervision: Xiusheng Qu.
Validation: Jing Li, Hai-bo Yu, Qing Xue, Xiusheng Qu.
Visualization: Zhi-ye Liu, Qing Xue, Xiusheng Qu.
Writing – original draft: Jing Li, Hai-bo Yu, Qing Xue, Xiusheng Qu.
Writing – review & editing: Jing Li, Zhi-ye Liu, Qing Xue, Xiusheng Qu.

References

[1] Yuan P, Chen TH, Chen ZW, et al. Calculation of life-time death probability due malignant tumors based on a sampling survey area in China. Asian Pac J Cancer Prev 2014;15:4307–9.
[2] Department of Medical Administration, National Health and Health Commission of the People’s Republic of China. Guidelines for diagnosis and treatment of primary liver cancer in China (2019 edition). Zhonghua Gan Zang Bing Za Zhi 2020;28:112–28.
[3] Kudo M, Izumi N, Kubo S, et al. Report of the 20th Nationwide follow-up survey of primary liver cancer in Japan. Hepatol Res 2020;50:13–46.
[4] Liu Z, Mao X, Jiang Y, et al. Changing trends in the disease burden of primary liver cancer caused by specific etiologies in China. Cancer Med 2019;8:5787–99.
[5] Ferlay J, Shin HR, Bray F, et al. Estimates of worldwide burden of cancer in 2008. GLOBOCAN 2008. Int J Cancer 2010;127:2893–917.
[6] Petrick JL, McGlynn KA. The changing epidemiology of primary liver cancer. Curr Epidemiol Rep 2019;6:104–11.
[7] Omata M, Cheng AL, Kokudo N, et al. Asia-Pacific clinical practice guidelines on the management of hepatocellular carcinoma: a 2017 update. Hepatol Int 2017;11:317–70.
[8] Kuzuya T, Ishigami M, Ito T, et al. Initial experience of ramucirumab treatment after lenvatinib failure for patients with advanced hepatocellular carcinoma. Anticancer Res 2020;40:2089–93.
[9] Wang J, Yan C, Fu A. A randomized clinical trial of comprehensive education and care program compared to basic care for reducing anxiety and depression and improving quality of life and survival in patients with hepatocellular carcinoma who underwent surgery. Medicine (Baltimore) 2019;98:e17552.
[10] Kaibori M, Matsui K, Yoshii K, et al. Perioperative exercise capacity in chronic liver injury patients with hepatocellular carcinoma undergoing hepatectomy. PLoS One 2019;14:e0221079.
[11] Wang J, Luo J, Yin X, et al. Jedu granule combined with transcatheter arterial chemoembolization and gamma knife radiosurgery in treating hepatocellular carcinoma with portal vein tumor thrombus. Biomed Res Int 2019;2019:4696843.
[12] Yoon SM, Ryou BY, Lee SJ, et al. Efficacy and safety of transarterial chemoembolization plus external beam radiotherapy vs sorafenib in hepatocellular carcinoma with macroscopic vascular invasion: a randomized clinical trial. JAMA Oncol 2018;4:661–9.
[13] Ng KKC, Chok KSH, Chan ACY, et al. Randomized clinical trial of hepatic resection versus radiofrequency ablation for early-stage hepatocellular carcinoma. Br J Surg 2017;104:1775–84.
[14] Martinelli I, Ponzi FR, Manzo A, et al. Thrombosis after liver transplantation for hepatocellular carcinoma. PLoS One 2017;12:e0186699.
[15] Ma W, Wu L, Zhou F, et al. T cell-associated immunotherapy for hepatocellular carcinoma. Cell Physiol Biochem 2017;41:609–22.
[16] Yang JH, Feng BM, Han XL, et al. The effect of artemisinin on the proliferation, apoptosis and β-catenin protein expression of liver cancer HepG2 cells. Chin Pharmacol Bull 2019;35:1659–64.
[17] Han L, Yang Y, Fu Y, et al. The effect of dihydroartemisinin on the proliferation of liver cancer HepG2 cells by regulating the PTEN/Akt signaling pathway. Guangdong Chem Ind 2019;46:21–2.
[18] Li YW, Zhang W, Li Y, et al. Molecular mechanism of artemisinin-induced apoptosis of human hepatoma cell HepG2 through the mitochondrial pathway. J Toxicol 2018;32:194–8.
[19] Zheng JY. Artemisinin inhibits the tolerance of CD133 + HepG2 cells to (I)T cells and its mechanism. Zhejiang J Integr Tradit Chin West Med 2017;27:1035–9.
[20] Zhang H, Zhang T, Fan YS, et al. The effect of artemisinin combined with cisplatin on inhibiting the proliferation of liver cancer cell HepG2. J Toxicol 2016;30:435–40.
[21] Yue XQ, Xu CF, Hu XL, et al. The effect of artemisinin on the proliferation of human liver cancer HepG2 cells. J Jilin Med Coll 2016;37:191–3.
[22] Huang JL, Li GZ, Huang ZS, et al. The effect of artemisinin on the proliferation of hepatoma cell line HepG2. Chongqing Med 2015;44:21–3.
[23] Wang Q, Wu H. Experimental study of the effect of dihydroartemisinin on the growth of human hepatoma cell line HepG2 in vitro. China Med Front 2012;7:9–10.
[24] Shamseer L, Moher D, Clarke M, et al. PRISMA-P Group. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ 2015;349:g7647.
[25] Moher D, Shamseer L, Clarke M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.